GSK two melanoma drugs approved in China
-
Last Update: 2015-01-28
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
GlaxoSmithKline's Lama single drug was approved for clinical use last week, and it continued to work this week Two drugs for melanoma were approved for clinical use by CFDA The trametinib tablets and dabrafenib capsules declared by GlaxoSmithKline left the newly reported task sequence on January 20 and were approved for clinical application on January 21 Traitinib and dabrafenib are MEK1 / 2 inhibitors and BRAF protein kinase inhibitors respectively, which were approved by FDA on May 29, 2013 They are used as a single treatment drug in patients with metastatic melanoma with BRAF V600E (or v600k) mutation The FDA granted the qualification of traitinib and dabrafenib orphan drugs In addition, the application of traitinib and dabrafenib for the treatment of melanoma also obtained the priority review qualification of FDA, and was approved on January 8, 2014 However, the fate of the two drugs in the EU is not so smooth Although the single drug treatment of melanoma was approved by the EU, and was launched in June 2014 and August 2013 respectively, GSK withdrew the application of the two drug combination program before, and said that it would resubmit the application when there are more data in phase III clinical trials We need to wait for a while to know the fate of these two drugs in China
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
